SAN JOSE, CA., June 23, 2022 /PRNewswire/ — CPC Scientific Inc., a world leader in CRDMO (Contract Research, Development, and Manufacturing Organization) peptides, has invested in a new API (Active Pharmaceutical Ingredient) peptide manufacturing facility, bringing many new jobs to Rocklin, California. The 41,000 square foot facility located at 3880 Atherton Rd, Rocklin, California 95765 will be used to manufacture clinical to commercial grade peptide products for increased manufacturing capacity and will diversify CPC Scientific’s supply chain.
“CPC Scientific is entering an exciting period of growth and innovation for the development and manufacturing of therapeutic peptides and oligonucleotides, and we will continue to provide therapeutic APIs to pharmaceutical and biotechnology companies worldwide. We are very happy to be associated with the Town of Rocklin, California to bring manufacturing and life science jobs to local American workers,” said Shawn LeePh.D., CEO.
Expand CPC Scientific’s manufacturing footprint by North America allows them to continue to produce innovative peptide products while delivering additional capacity to specialty peptide APIs more quickly.
Peptide-based therapeutic candidates have been the fastest growing area among all chemical synthesis NCEs (New Chemical Entities) for new drug development in recent years. For more than two decades, CPC Scientific has been a trusted partner to customers around the world, including multinational pharmaceutical companies, biotechnology companies and academic institutions, providing one-stop, value-added development and manufacturing services. to support their clinical trials. CPC Scientific has successfully provided commercial APIs to its customers in the United States, Europe, Australia, Japanand China for their peptide-based drugs and medical devices. By expanding its GMP manufacturing footprint, CRDMO will provide its customers and partners with multiple geographic options to ensure a secure API supply chain.
“We have helped many of our customers bring an innovative drug to market from a concept. With the new rocklin site, we believe that we will be able to contribute more particularly to the North American market and we will continue to deploy our efforts through our decades of expertise in peptide synthesis to help our customers save lives and improve human health around the world,” said Shawn Leedoctorate
The new Rocklin CGMP facility is expected to be online and fully operational by 2023. With manufacturing operations at Hangzhou (NC) and Rocklin, California (USA), these facilities will enable CPC Scientific to help meet the growing global demand for peptide-based therapeutics and diagnostics.
About CPC Scientific.
Founded in 2001, CPC Scientific is a world-renowned CRDMO specializing in the production of synthetic peptides, which is also expanding its footprint in synthetic oligonucleotides. The company works directly with leaders in the biotechnology and pharmaceutical industries to help bring life-changing therapies and diagnostics to market. CPC Scientific has the ability to serve customers from the early stages of drug discovery, through clinical trials, to commercial manufacturing, and is proud to provide commercial APIs to our partners around the world. Dozens of isolated process and purification suites for peptide manufacturing enable simultaneous projects of multiple, multi-kilogram batches. With a focus on technology, innovation and experience, we are proud to have our facilities inspected by numerous government agencies, including the United States Food and Drug Administration (FDA).
Press release issued by PRLog
SOURCE CPC Scientific Inc.